BPG is committed to discovery and dissemination of knowledge
Review
Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 127405
Published online Nov 24, 2026. doi: 10.5306/wjco.127405
Table 2 Summary of the safety and efficacy of treatments for colorectal cancer according to the three sex, seniors, and sarcopenia
Outcome
Setting
Women (vs men)
Fit, aged (vs younger)
Sarcopenia/reduced skeletal muscle (vs no sarcopenia)
SafetyPalliative chemotherapyIncreased gastrointestinal and hematological toxicities (5-FU, oxaliplatin, irinotecan)Increased diarrhea and neutropenia (5-FU, oxaliplatin, irinotecan)Increased neurological, gastrointestinal and hematological toxicities
Increased nausea (trifluridine/tipiracil)No difference (trifluridine/tipiracil)Frequent DLT (5-FU, oxaliplatin)
No difference (anti-VEGF)Increased thrombocytopenia (bevacizumab)Frequent DLT (regorafenib)
No different toxicity (anti-EGFR)No different toxicity (fruquintinib)
Increased fatigue, hypertension, skin toxicity, and anorexia (regorafenib)Increased diarrhea, frequent body weight loss (aflibercept)
No different toxicity (T-Dxd)No different toxicity (regorafenib)
Severer irAEs (ICIs)
ChemoradiotherapyFrequent interruption and discontinuationFrequent dose reductionProbable increased cystitis and thrombocytopenia
Increased diarrhea, perianal dermatitis, and hematological toxicitiesNo different toxicity
Adjuvant chemotherapyFrequent dose reduction (5-FU, oxaliplatin). Decreased completion rate (oxaliplatin)No different toxicity (5-FU)Decreased completion rate (oxaliplatin)
Probable increased toxicity (oxaliplatin)Frequent DLT (oxaliplatin)
EfficacyPalliative chemotherapyComparable PFS and OS (5-FU, oxaliplatin)Comparable RR and OS (5-FU)Poorer PFS and OS (5-FU, oxaliplatin)
Comparable PFS and OS (ICIs)Comparable RR and undermined survival benefit (oxaliplatin, irinotecan)
Comparable PFS and OS (trifluridine/tipiracil)
Comparable PFS and undermined survival benefit (bevacizumab)
Comparable OS (ramucirumab, aflibercept, fruquintinib)
Comparable RR and PFS (anti-EGFR)
Comparable RR and PFS (T-Dxd)
No survival benefit (pembrolizumab)
Comparable PFS (nivolumab + ipilimumab)
ChemoradiotherapyComparable tumor regression and pathological responseComparable tumor regression and pathological responseUndetermined impact on response
Adjuvant chemotherapyBetter DFS, RFS, and OS (5-FU, oxaliplatin)Comparable survivals (5-FU)Undetermined survival benefit (5-FU, oxaliplatin)
Undetermined survival benefit (oxaliplatin)


Write to the Help Desk